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Abstract  1 
Background:  2 
Exercise mobilizes angiogenic cells, which stimulate vascular repair. However, limited 3 
research suggests exercise-induced increase of endothelial progenitor cell (EPCs) is completely 4 
lacking in type 1 diabetes (T1D). Clarification, along with investigating how T1D influences 5 
exercise-induced increases of other angiogenic cells (hematopoietic progenitor cells; HPCs) 6 
and cell surface expression of chemokine receptor 4 (CXCR4) and 7 (CXCR7), is needed. 7 
Methods: 8 
Thirty T1D patients and 30 matched non-diabetes controls completed 45 minutes of incline 9 
walking. Circulating HPCs (CD34+, CD34+CD45dim) and EPCs (CD34+VEGFR2+, 10 
CD34+CD45dimVEGFR2+), and subsequent expression of CXCR4 and CXCR7, were 11 
enumerated by flow cytometry at rest and post-exercise. 12 
Results: 13 
Counts of HPCs, EPCs and expression of CXCR4 and CXCR7 were significantly lower at rest 14 
in the T1D group.  In both groups, exercise increased circulating angiogenic cells. However, 15 
increases was largely attenuated in the T1D group, up to 55% lower, with CD34+ (331±437 16 
Δcells/mL vs 734±876 Δcells/mL p=0.048), CD34+VEGFR2+ (171±342 Δcells/mL vs 17 
303±267 Δcells/mL, p=0.006) and CD34+VEGFR2+CXCR4+ (126±242 Δcells/mL vs 218±217 18 
Δcells/mL, p=0.040) significantly lower.   19 
Conclusion: 20 
Exercise-induced increases of angiogenic cells is possible in T1D patients, albeit attenuated 21 
compared to controls. Decreased mobilization likely results in reduced migration to, and repair 22 
of, vascular damage, potentially limiting the cardiovascular benefits of exercise. 23 
Trial registration: ISRCTN63739203 24 
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Endothelial progenitor cells (EPCs), first discovered in 1997, are mononuclear cells which have 2 
the potential to stimulate vascular repair1. Evidence demonstrates that these cells can 3 
differentiate into endothelial cells in vitro1,2, incorporate into sites of angiogenesis in vivo3,4 4 
and exert proangiogenic abilities via paracrine action2. First identified as cells in peripheral 5 
blood expressing CD34, a marker of haematopoiesis5, these precursor cells are now known as 6 
haematopoietic stem/progenitor cells (HPC). It is suggested that a more focused phenotype that 7 
includes endothelial markers, such as VEGFR2, identifies a sub-population that can 8 
differentiate into endothelial cells and therefor are true EPCs6.  9 
The number and function of both HPCs and EPCs are clinically relevant, with lower 10 
concentrations associated with endothelial dysfunction7 and a greater risk of cardiovascular 11 
events and mortality8,9. Within individuals with type 1 diabetes, most10–13, but not all studies14, 12 
have found reduced circulating numbers of HPCs and EPCs compared to matched non-diabetes 13 
controls. In combination with hyperglycemia and glucose fluctuations, it is possible that 14 
dysfunctional HPCs and EPCs contribute to increased vascular damage15,16 and progression of 15 
micro and macrovascular complications17, with individuals with type 1 diabetes having a 2- to 16 
8-fold increase in mortality rates compared with the general population largely due to 17 
cardiovascular diseases (CVD)18–20. Whilst improved glycemic control is associated with 18 
reduced development of CVD21, incidence remains elevated even in individuals who have 19 
successfully addressed modifiable risk factors18.  20 
In healthy individuals, acute exercise can mobilize both HPCs and EPCs into circulation, and 21 
improve their angiogenic function22–24. However, exercise-induced increases of EPCs appears 22 
attenuated in those with chronic diseases25,26, which may partially explain the increased CVD 23 
risk in these populations. Indeed, increased pre-operative exercise-induced mobilization of 24 
EPCs is correlated with reduced post-operative complications after major thoracic surgery27, 25 
while HPCs response to exercise was a stronger predictor of myocardial ischemia and mortality 26 
than resting circulating count in patients with coronary artery disease over a subsequent 3 year 27 
period28. Insight into the ability of these cells to respond to a stimulus, such as exercise, 28 
migrating into circulation and homing to ischemic tissue can be measured by the surface 29 
expression of chemokine (C-X-C motif) receptor 4 (CXCR4) and 7 (CXCR7)29,30, although 30 
evidence on the influence of type 1 diabetes is lacking. Within other chronic diseases, 31 
diminished number of CD34+CXCR4+ cells may be a better predictor of mortality than CD34+ 32 
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cells alone9, while the expression of CXCR7 has been linked to cell survival in diabetic 1 
condition in vitro, although limited evidence exists in human studies30. 2 
While mobilisation of HPCs and EPCs appears attenuated to direct stimulation in both type 1 3 
and 2 diabetes31,32, and exercise-induced increases appears attenuated in type 2 diabetes26, there 4 
is limited information in Type 1 diabetes, a vastly different disease. Type 1 diabetes patients 5 
are typically not obese, tend to be diagnosed at an early age (if not childhood), and generally 6 
live much more active lives with higher levels of cardio-respiratory fitness33, albeit slightly 7 
lower than the general non-diabetes general public34. At present, the two studies that have had 8 
investigated EPC mobilization with acute exercise in individuals with type 1 diabetes have 9 
found total lack of mobilisation35,36. However, as previous studies have measured EPCs as a 10 
percentage of circulating mononuclear cells, where any mobilization is likely masked by 11 
increases in overall leucocyte counts with exercise37, they failed to capture the expected post-12 
exercise mobilization in the non-diabetes controls.  13 
Thus, due to the increased risk of vascular complications in this disease, this study aimed to 14 
definitely explore whether exercise-induced increases of HPCs and EPCs is possible for people 15 
with type 1 diabetes. Additionally, this study aimed to explore how type 1 diabetes influences 16 
deeper phenotypes of angiogenic cells, including not previously measured cell surface 17 
expression of key chemotactic receptors CXCR4 and CXCR7, comparing to age-, sex-, fitness- 18 
and BMI- matched controls at rest and during exercise-induced mobilisation. We hypothesized 19 
that the type 1 diabetes group will have reduced resting and exercise-induced increases of HPCs 20 













Participants were recruited from the Newcastle Diabetes Centre and Newcastle University. 3 
Participants with type 1 diabetes had a confirmed clinical diagnosis; age 18-65 years with a 4 
diabetes duration ≥3 years; HbA1c <86 mmol/mol (10.0%); and absence of diabetes-related 5 
complications apart from non-proliferating retinopathy. Eligibility criteria for the non-diabetes 6 
participants comprised being aged between 18-65 years, non-smoker, and free from any history 7 
of chronic diseases. 8 
All participants provided written informed consent and the study was approved by the NHS 9 
HRA North East Tyne & Wear South Research Ethics and Newcastle University Ethics 10 
Committees (code:16/NE/0192, registry:ISRCTN63739203). All methods were performed in 11 
accordance with the relevant guidelines and regulations. 12 
Screening Visit 13 
All participants attended the Newcastle NIHR Clinical Research Facility (CRF) on two 14 
occasions. Firstly, a screening visit to determine eligibility, medical assessment and peak 15 
oxygen uptake (?̇?𝑉O2peak). Participant height, body mass (Seca 220 stadiometer / Seca 889 scales, 16 
Seca, Germany) and medical history were taken. Participants underwent a modified 12-lead 17 
resting and exercising electrocardiogram to screen for cardiac abnormalities. Eligible 18 
participants completed a maximal graded exercise treadmill (Valiant 2 CPET, Lode, 19 
Groningen, Netherlands) test using the Bruce protocol38 to determine ?̇?𝑉O2peak. Glucose levels 20 
in participants with type 1 diabetes were managed as per the guidance of Riddell et al.39  21 
Main Trial Visit 22 
Participants attended the CRF at least 7 days after the initial screening. Individuals arrived at 23 
the exercise lab at ~8.30am after an overnight fast, having been instructed to avoid structured 24 
exercise in the 48 hours preceding the visit.  25 
The participants with type 1 diabetes maintained their normal basal insulin regimen. If they 26 
experienced a hypoglycemic event overnight prior to the study visit, the visit was reorganised. 27 
If blood glucose on waking was >10 mmol/L, they were instructed to have a small corrective 28 
bolus of rapid-acting insulin (≤2 units). 29 
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Upon arrival, the non-dominant arm of each participant was cannulated and resting (baseline) 1 
blood samples were drawn. The initial 4 mL drawn was discarded to avoid contamination of 2 
mature circulating endothelial cells with cells released from the punctured vein during the 3 
cannulation. One 10 mL EDTA vacutainer (Becton, Dickinson and Company, New Jersey, 4 
USA) was collected at baseline and, immediately post-exercise. An additional 4 mL EDTA 5 
Vacutainer was drawn at baseline for analysis of HbA1c at the Newcastle Clinical Laboratory. 6 
Capillary blood was collected at all-time points and analysed by a HemoControl analyser (EKF, 7 
Cardiff, UK) to determine haematocrit and haemoglobin concentration. 8 
Participants consumed a 30g carbohydrate snack (Belvita, Mondelēz International, USA) 9 
immediately after baseline blood draws and remained rested for 20 minutes. Participants 10 
walked on an incline for 45 minutes at 60% ?̇?𝑉O2peak at a comfortable stride length (8.06 ± 11 
5.09% at 4.30 ± 0.47 kph). Participants’ treadmill velocity and gradient were calculated using 12 
?̇?𝑉O2, velocity, and gradient data from the preliminary ?̇?𝑉O2peak test40. Breath-by-breath 13 
respiratory parameters (Metalyzer 3B-R3 CPET, Cortex, Leipzig, Germany) were continuously 14 
recorded throughout, with gradient adjusted at 10 and 30 minutes if ?̇?𝑉O2  was >10% different 15 
than target ?̇?𝑉O2. Participants with type 1 diabetes had a target capillary blood glucose >7 16 
mmol/L for the duration of the exercise with 6 individuals given 10g of additional 17 
carbohydrates, administered via a glucose drink. 18 
Upon completion of the exercise, venous blood samples were immediately drawn from the 19 
cannula. Participants rested for 60 minutes before another venous blood sample was drawn and 20 
being discharged from the CRF if capillary blood glucose concentration >3.9 mmol/L (70 21 
mg/dL). 22 
 23 
Flow Cytometry Enumeration of Hematopoietic and Endothelial Progenitor Cells 24 
HPCs and EPCs were quantified on a flow cytometer (BD LSRFortessa X20; BD Biosciences, 25 
USA) within 4 hours of blood draw6. Briefly, 200 µL of whole peripheral blood collected in 26 
EDTA was incubated with 10 µL anti-CD34 FITC, 10 µL anti-VEGFR2 APC, 10 µL anti-27 
CD45 BV421 (BioLegend, San Diego, CA, USA), 10 µL anti-CXCR4 APC Cy7, and 10 µL 28 
anti-CXCR7 PE (BioLegend, San Diego, CA, USA) in a BD Trucount (BD Biosciences, USA) 29 
tube at 4°C for 30 minutes in the dark. Four mL of red blood cell lysis buffer (BD Pharm 30 
LyseTM, BD Biosciences, United Kingdom) was added and left to incubate for a further 30 31 
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minutes at 4°C in the dark before enumeration by flow cytometry. The samples were vortexed 1 
at low speed to resuspend beads and reduce cell aggregation. Samples were analysed for 45 2 
minutes or until 500,000 CD45+ events had been enumerated, whichever occurred first. The 3 
LSRFortessa was equipped with a blue, yellow/green, red, violet and ultra violet lasers (488nm, 4 
561nm, 635nm, 405nm and 355nm wavelengths, respectively). 5 
Compensation using BD CompBead (BD Biosciences, USA), was performed prior to 6 
collecting each participant’s data to correct for any spectral overlap. Due to highly unreliable 7 
nature of isotype controls in rare event analysis6, positive (VEGFR2) and negative (VEGFR2, 8 
CXCR4, CXCR7) control samples were used to help determine the gating of positive events 9 
by histogram and dot plot (Figure 1F,H,J). Between samples, FACS clean (BD Biosciences, 10 
USA) and deionized water was used to decontaminate the flow cytometer for 5 minutes.  11 
 12 
Following data acquisition, flow cytometry files were analysed using FCS Express 7 (De Novo, 13 
California, USA). Counts of HPC and EPC numbers were converted to cells/mL using BD 14 
Trucount, with the number of positive cell events divided by the number of Trucount bead 15 
event, and then multiplying by the known total BD Trucount bead concentration. Haematocrit 16 
and haemoglobin concentration measures were used to adjust absolute cell counts changes in 17 
blood volume using the Dill and Costill method41. Instead of presenting as a proportion of total 18 
events enumerated by flow cytometry, a valid methodology for the measuring of rare cells at 19 
rest6, the use of Trucount tubes permits the acquisition of absolute cell counts of cells, and 20 
allows the exact changes in response to a stimulus to be measured. As overall leucocyte counts 21 
acutely increase with exercise37, any changes in rare cells are likely masked or hidden when 22 
measure as a percentage of total events.  23 
The gating strategies for enumeration of the HPCs (CD34+, CD34+CD45dim)5 and EPCs 24 
(CD34+VEGFR2+, CD34+CD45dimVEGFR2+)6,42 and subsequent cell surface expression of 25 
CXCR4 and CXCR7 are displayed in Figure 1. Selected time-points were run in duplicate, with 26 
blood from a single vacutainer separated and fluorescent-labelled antibodies added before 27 
analysis by flow cytometry, with an intra-individual CV% of 8.68%.  28 
 29 
 30 





Statistical Analysis 3 
Statistically significant differences between the type 1 diabetes and non-diabetes control group 4 
were determined by independent sample T-test. Data were assessed for normality and outliers 5 
by box-plots and Shapiro-Wilk test. Excessively skewed data were transformed using square 6 
root and logarithmic transformation. When transformation failed, group difference data were 7 
assessed by Mann-Whitney U Test. Time course change data (pre, immediately post and 1 hour 8 
post exercise) was analysed by mixed-effects model. GraphPad Prism 8.0.1 (San Diego, USA) 9 
and IBM SPSS Statistics (version 24, IBM, Armonk NY) software packages were used to 10 
analyse the data. Statistical significance set at p≤0.05. Data are presented as mean ± standard 11 



















Demographic data are shown in Table 1. Age, BMI and ?̇?𝑉O2peak were comparable between the 2 
matched groups.  3 
Table 1. Participant demographic data.  4 
 Type 1 diabetes group Non-diabetes control group p-value 
N 30 30  
Male/female 16/14 16/14  
Age (years) 38.2 ± 12.0 37.6 ± 12.1 0.840 
HbA1c (mmol/mol) 58.5 ± 9.1 33.5 ± 2.3  < 0.001 
(%) 7.5 ± 3.0 5.2 ± 2.4 < 0.001 
BMI (kg/m2) 25.2 ± 3.7 24.7 ± 4.6 0.656 
?̇?𝑽O2peak (ml/kg/min) 38.8 ± 9.5 42.4 ± 12.4 0.205 
Age at diagnosis 18.2 ± 8.6 -  
Range (years) 8 to 35   
Duration of diabetes 20.0 ± 13.0 -  
Range (years) 3 to 47   
Method of control 
(MDI/CSII) 15/15 - 
 
Data presented as mean ± SD. P value from independent samples t-test 5 
 6 
On average, participants exercised at 58.8% of their ?̇?𝑉O2peak, with no differences between the 7 
groups (p= 0.907). There were no episodes of hypoglycemia (<3.9 mmol/L) during the exercise 8 
bout.  9 
 10 
Resting Levels of Circulating HPCs and EPCs are Lower in the Participants with Type 1 11 
Diabetes than Non-Diabetes Controls 12 
Circulating numbers of HPCs CD34+ (type 1 diabetes; 1468 ± 611 cells/mL, CON; 2048 ± 768 13 
cells/mL, p= 0.001) and CD34+CD45dim (type 1 diabetes; 1189 ± 536 cells/mL, CON; 1684 ± 14 
765 cells/mL, p= 0.003) were significantly lower at rest in the type 1 diabetes group compared 15 
to the non-diabetes controls (Figure 2.A). Resting counts of EPCs CD34+VEGFR2+ (type 1 16 
diabetes; 411 ± 159 cells/mL, CON; 664 ± 217 cells/mL, p< 0.001) and 17 
CD34+CD45dimVEGFR2+ (type 1 diabetes; 292 ± 121 cells/mL CON; 462 ± 177 cells/mL, p< 18 
0.001) were also significantly lower at rest within the type 1 diabetes group compared to the 19 
non-diabetes controls (Figure 2.A). Additionally, circulating number of all HPCs and EPCs 20 
10 
 
expressing CXCR4 and CXCR7 were significantly lower in the type 1 diabetes group than the 1 
matched non-diabetes controls (Figure 2.B+C).  2 
 3 
 4 
 ***Insert Figure 2*** 5 
 6 
 7 
When expressed as a percentage of the HPC and EPC phenotypes, CXCR4 expression at rest 8 
tended to be similar between groups. However, percentage of CD34+CD45dimVEGFR2+ 9 
expressing CXCR4 was significantly higher in in the type 1 diabetes group (p= 0.050) (Figure 10 
3.A). Percentage of cells expressing CXCR7 at rest tended to be lower in the type 1 diabetes 11 
group, with CD34+CXCR7+ significantly so (p= 0.035) (Figure 3.B). 12 
 13 
***Insert Figure 3*** 14 
  15 
 16 
 17 
Type 1 Diabetes Patients Display Attenuated HPC and EPC Mobilization in Response to Acute 18 
Exercise 19 
The mean delta change (Δ) in pre to post-exercise cell numbers is displayed in Figure 4. The 20 
type 1 diabetes group had attenuated mobilization of HPCs and EPCs, ranging from 39 to 55% 21 
lower across the phenotypes when compare to the non-diabetes group, with CD34+ HPCs (331 22 
± 437 Δ cells/mL vs 734 ± 876, Δ cells/mL p= 0.048) and CD34+VEGFR2+ EPCs (171 ± 342 23 
Δ cells/mL vs 303 ± 267 Δ cells/mL, p= 0.006) significantly lower.  24 
There were no significant differences between the groups in the Δ of CXCR4+ or CXCR7+ 25 
HPC and EPC phenotypes (p> 0.05), other than for CD34+VEGFR2+CXCR4+ EPCs, where the  26 
mobilization in the type 1 diabetes group was 42% lower compared to controls (126 ± 242 Δ 27 
cells/mL vs 218 ± 217 Δ cells/mL, p= 0.040).  28 
11 
 
***Insert Figure 4*** 1 
 2 
Within the type 1 diabetes group, exercised-induced increases of the HPCs and EPCs was 3 
significantly greater in the cells that also expressed CXCR4 or CXCR7, with the progenitor 4 
cells negative for a chemokine receptor having between 64 to 101% less mobilization (Table 5 
2). In comparison, within the controls, only the CD34+VEGFR2+ EPCs positive for CXCR4 6 
had significantly higher mobilization than the CXCR4 negative cells (218 ± 217 Δ cell/mL vs 7 
85 ± 143 Δ cell/mL, p= 0.007). Additionally, the CD34+VEGFR2+  and  8 
CD34+CD45dimVEGFR2+ EPCs positive for CXCR7 also had significantly greater 9 
mobilization than those negative for CXCR7 (248 ± 213 Δ cell/mL vs 55 ± 132 Δ cell/mL, p< 10 
0.001 and 166 ± 158 Δ cell/mL vs 46 ± 112 Δ cell/mL, p= 0.005, respectively).  11 
 12 
Table 2. Mean delta change (Δ) in pre to post-exercise cell numbers of HPCs and EPCs 13 
expressing CXCR4 and CXCR7 versus those negative for CXCR4 and CXCR7 for the type 1 14 
diabetes and control groups.   15 
Data presented as mean ± SD. P value from dependent samples t-test 16 
 17 
Time Course Kinetics and Association Between Clinical Variables and Resting and 18 
Exercise-Induced Progenitor Cell Number 19 
All HPC and EPC phenotypes, and their cell surface expression of CXCR4 and CXCR7, had a 20 
main effect of time with immediately post-exercise sample significantly higher than the 21 
baseline samples (p< 0.002). Additionally, CD34+, CD34+CXCR4+, CD34+CXCR7+  HPCs had 22 
a significantly higher count 1-hour post-exercise compared to pre-exercise levels (p= 0.042, p= 23 
 CXCR4+ CXCR4- p CXCR7+ CXCR7- p 
Type 1 Diabetes Group       
CD34+ 297 ± 378 34 ± 268 0.006 286 ± 383 45 ± 293 0.018 
CD34+CD45dim 237 ± 333 40 ± 267 0.031 203 ± 283 74 ± 279 0.105 
CD34+VEGFR2+ 126 ± 242 44 ± 178 0.084 171 ± 298 -1 ± 85 0.002 
CD34+CD45dimVEGFR2+ 124 ± 186 5 ± 75 0.003 130 ± 175 -1 ± 75 <0.001 
Control Group       
CD34+ 332 ± 337 403 ± 641 0.468 337 ± 348 397 ± 766 0.686 
CD34+CD45dim 206 ± 278 391 ± 631 0.173 227 ± 243 380 ± 631 0.311 
CD34+VEGFR2+ 218 ± 217 85 ± 143 0.007 248 ± 213 55 ± 132 <0.001 
CD34+CD45dimVEGFR2+ 130 ± 161 82 ± 131 0.276 166 ± 158 46 ± 112 0.005 
12 
 
0.010 and p= 0.013, respectively). There was a group x time interaction for the CD34+ HPCs, 1 
remaining elevated at 1hr post exercise in the type 1 diabetes group but not the healthy controls 2 
(Supplementary Figure 1).  3 
Clinical variables (HbA1c, BMI, age, ?̇?𝑉O2peak, age at diagnosis and duration of diabetes) were 4 
assessed for correlations with resting concentrations and Δ from pre- to post-exercise 5 
(cells/mL) (Supplementary Table 1 + 2). HbA1c was negatively correlated with HPC and EPC 6 
concentration at rest for all participants (n=60, r>-0.272, p<0.036). However, when split into 7 
the type 1 diabetes (n=30) and non-diabetes control (n=30) groups, the relationships were no 8 
longer significant, except for HbA1c and CD34+CD45dimVEGFR2+CXCR7+ EPCs (r= -0.364, 9 
p= 0.048) in the type 1 diabetes group. An older age of type 1 diabetes diagnosis positively 10 
correlated with CD34+CD45dim cells (r= 0.361, p= 0.050). Within the type 1 diabetes group, no 11 















We investigated the influence of type 1 diabetes on circulating HPC and EPC numbers, and the 27 
cell surface expression of CXCR4 and CXCR7 on these cells, at rest and in response to a 28 
13 
 
submaximal exercise bout. For the first time, we demonstrate that individuals with type 1 1 
diabetes are able to increase HPCs and EPCs into circulation in response to exercise. However, 2 
mobilization of these angiogenic cells is attenuated in comparison to matched non-diabetes 3 
controls, which may play a role in the increased risk of vascular complications seen in type 1 4 
diabetes   5 
Our primary finding that individuals with type 1 diabetes can mobilize HPCs and EPCs in 6 
response to exercise is of interest, as exercise-induced mobilization has been shown to be a 7 
more powerful predictor of complications and mortality than basal circulating count in thoracic 8 
surgery and coronary artery disease patients27,28, and contrasts previous research which found 9 
no mobilisation of EPCs in type 135,36 or 2 diabetes26. Differences between our study and those 10 
previously exploring exercise-induced mobilisation in people with type 1 diabetes likely arose 11 
due to alternative ways of quantifying circulating angiogenic cell numbers. While our study 12 
used BD Trucount tubes to calculate absolute cell counts and adjusted these results for changes 13 
in blood volume41, accurately determining cell changes in response to an exercise stressor, 14 
previous studies have only measured circulating EPCs as a percentage of circulating 15 
mononuclear cells, where any exercise-induced mobilization was likely concealed by increases 16 
in overall leucocyte counts around exercise37. Additionally, we included a much deeper 17 
examination of angiogenic cell phenotypes, demonstrating that both HPCs and EPCs are 18 
mobilised by individuals with type 1 diabetes. 19 
These results again demonstrate that type 1 diabetes has a detrimental impact on circulating 20 
EPCs and HPCs, with previous research demonstrating a reduced resting count10–12 and 21 
impaired angiogenic function including: impaired ability to differentiate into endothelial cells, 22 
reduced migration to areas of ischemia, reduced angiogenic paracrine secretion, and increased 23 
apoptosis43. As these circulating cells play an important role in maintaining endothelial 24 
integrity7, the reduced circulating numbers seen in this study may play an important causative 25 
role in the development of diabetic complications and increased CVD through reduced 26 
endothelial repair8, with lower levels of both HPCs and EPCs counts associated with extensive 27 
multi-site atherosclerosis44. Our study is the first to demonstrate that circulating numbers of 28 
these angiogenic cells expressing CXCR4 and CXCR7 are also significantly lower in 29 
individuals with type 1 diabetes, findings similar to those seen in people with type 2 diabetes45. 30 
The reduced number of cells expressing CXCR4 and CXCR7 likely results in the reduced 31 
ability to migrate into circulation and to ischemic tissue within diabetes29,30,46, which may 32 
14 
 
further exacerbate endothelial dysfunction and microvascular abnormalities and increase the 1 
risk of mortality47.    2 
Within our study, both groups were well matched, the participants were not obese or old, and 3 
had moderate cardiorespiratory fitness (38.8 ± 9.5 mL/min/kg), which contrasts enormously to 4 
work conducted exploring exercise-induced mobilisation of EPCs in type 2 diabetes26. 5 
Additionally, our participants with type 1 diabetes had no major diabetes-related complications. 6 
Despite this, we showed that the increased circulating HPCs and EPCs from pre- to post-7 
exercise in the type 1 diabetes group, CD34+ HPCs, CD34+VEGFR2+, 8 
CD34+VEGFR2+CXCR4+ EPC counts were significantly attenuated compared to the non-9 
diabetes controls. Strikingly, mean post-exercise concentrations of most the phenotypes were 10 
lower in the type 1 diabetes group than the resting concentrations of the controls.  The reduced 11 
exercise-induced mobilization is similar to previous studies that found no mobilisation of  12 
HPCs and EPCs to indirect CXCR4+ stimulation31 and slightly attenuated mobilisation to direct 13 
CXCR4+ antagonists  in a mixed group of type 1 and 2 diabetes participants32. It is unclear why 14 
a direct CXCR4+ antagonist can mobilise angiogenic cells from the bone marrow while an 15 
indirect cannot. As exercise mobilised HPCs and EPCs negative for CXCR4 and CXCR7 in 16 
the controls, but not the type 1 diabetes group, this suggests pathways other than stromal cell–17 
derived factor-1α (SDF-1α)/CXCR4 are also impaired by deregulated glucose control seen in 18 
diabetes. 19 
While the exact mechanism for mobilising angiogenic cells in response to exercise has not been 20 
fully elucidated, mobilization is dependent on both duration and intensity, with a higher 21 
intensity potentially needed in this study in order for all participants to achieve mobilisation23. 22 
Post-exercise counts have been shown to positively correlate with increased circulating levels 23 
of SDF-1α, VEGF, erythropoietin and tissue expression of hypoxia-inducible factor 1-α. 24 
Suppressed release of VEGF and SDF-1α, key for the mobilization and homing of progenitor 25 
cells from the bone marrow to areas of ischemia, have been  demonstrated in a murine model 26 
of diabetes48, and may explain the reduced increase in HPCs and EPCs seen in this study. 27 
Additionally, high glucose conditions have been shown to reduce the angiogenic function of 28 
HPCs and EPCs49, as well as increasing senescence and apoptosis43. Within type 1 diabetes 29 
mouse models, it has been demonstrated that increased vascular damage ultimately results in 30 
the exhaustion and depletion of progenitor cells stored within the bone marrow. Moreover, 31 
dysfunctional osteoblastic niches and microangiopathy damage to the blood vessels in the bone 32 
resulting in an impaired ability to egress these cells into circulation in response to ischemia50. 33 
15 
 
Microvascular dysfunction and altered blood flow can occur in the early stages of Type 1 1 
diabetes, with hyperglycaemia and oxidative stress reducing the bioavailabilty of nitrix 2 
oxide51,52. Endothelial nitrix oxide synthase induces smooth muscle relaxition and blood vessel 3 
dilation, and is strong modulator of circulating angiogenic cells funtion and homing53. It has 4 
been demonstrated that pancreas transplants improves endothelial function in conjunction with 5 
the normalisation of glucose metabolism by restoring endothelial nitric oxide synthase54, which 6 
likely explains the post islet-transplant improvements in circulating angiogenic cell function55. 7 
This raises the intriguing possibility that exercise, improvements in glycemic control and 8 
vasodilatory dietary supplements could increase endothelial nitric oxide synthase, improving 9 
endothelial and angiogenic cells functions within people with type 1 diabetes, warranting 10 
further study56.  11 
There is growing evidence for separate and important functions of CXCR7, promoting 12 
endothelial proliferation and angiogenesis, and plying a critical role in the survival of EPCs. 13 
Our results are supported by the observations by Dai et al.,30 demonstrating that the percentage 14 
of EPCs expressing CXCR7 but not CXCR4 was reduced in a diabetes mouse and in vitro 15 
model, but not Vigorelli et al.,57 who showed reduced CXCR4 protein expression when 16 
exposing CD34+ cells to a high glucose environment in vitro. As knockdown of CXCR7 17 
impairs vascular tube formation and upregulation rescues angiogenic function of diabetic 18 
EPCs30, the reduction in CXCR7 angiogenic cells within this study is of clinical significance, 19 
highlighting the dysfunctional nature of these cells in people with type 1 diabetes.  The effect 20 
of glucose upon CXCR4 is controversial, with high glucose reported to both increase58 and 21 
inhibit expression59.  22 
Limitations of this study include the lack of an apoptosis marker, making it likely that non-23 
viable cells were quantified. This especially true of EPCs within the type 1 diabetes group, 24 
where increased apoptosis is likely due to hyperglycemia43, and mean fluorescence intensity of 25 
VEGFR2 staining is slightly greater in dead versus live cells60. Measuring progenitor cell 26 
mobilising stimuli would also have been beneficial, especially as the number of HPCs negative 27 
for a chemokine receptor mobilized with exercise was substantially lower in the type 1 diabetes 28 
group suggesting impairment of an additional pathway other than the SDF-1α/CXCR4 axis. 29 
Future research needs to explore whether different methods of diabetes management and 30 
improving glycemic control results in improvement in exercise-induced mobilization of these 31 
cells within individuals with type 1 diabetes. Improving HbA1c, and reducing glycemic 32 
variability (by switching diabetes management to continuous subcutaneous insulin infusion) 33 
16 
 
both increase basal concentrations of EPCs13,61, while severe hypoglycemia is associated with 1 
a marked depletion of circulating HPCs and EPCs in individuals with type 2 diabetes62.  2 
Potentially, they also influence exercise-induced mobilization. Regular exercise training, in 3 
both healthy and diseased populations, has also been shown to increase basal concentration of 4 
EPCs and HPCs62. Therefore, determining if exercise training could increase basal 5 
concentration and restore exercise-induced mobilization in individuals with type 1 diabetes, 6 
with the aim of improving vascular repair and reducing both micro and macrovascular diabetes 7 
complications merits further study.  8 
Conclusion 9 
In conclusion, people with type 1 diabetes have reduced resting and attenuated mobilization of 10 
EPCs and HPCs with exercise compared to matched controls. Reduced mobilization of HPCs 11 
and EPCs with exercise may play a role in the increased cardiovascular risk in individuals with 12 
type 1 diabetes. 13 
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Table 1. Participant demographic data.  1 
 Type 1 diabetes group Non-diabetes control group p-value 
N 30 30  
Male/female 16/14 16/14  
Age (years) 38.2 ± 12.0 37.6 ± 12.1 0.840 
HbA1c (mmol/mol) 58.5 ± 9.1 33.5 ± 2.3  < 0.001 
(%) 7.5 ± 3.0 5.2 ± 2.4 < 0.001 
BMI (kg/m2) 25.2 ± 3.7 24.7 ± 4.6 0.656 
?̇?𝑽O2peak (ml/kg/min) 38.8 ± 9.5 42.4 ± 12.4 0.205 
Age at diagnosis 18.2 ± 8.6 -  
Range (years) 8 to 35   
Duration of diabetes 20.0 ± 13.0 -  
Range (years) 3 to 47   
Method of control 
(MDI/CSII) 15/15 - 
 
Data presented as mean ± SD. P value from independent samples t-test 2 
 3 
Table 2. Mean delta change (Δ) in pre to post-exercise cell numbers of HPCs and EPCs 4 
expressing CXCR4 and CXCR7 versus those negative for CXCR4 and CXCR7 for the type 1 5 
diabetes and control groups.   6 
Data presented as mean ± SD. P value from dependent samples t-test 7 
 8 
 9 
Figures  10 
 11 
 CXCR4+ CXCR4- p CXCR7+ CXCR7- p 
Type 1 Diabetes Group       
CD34+ 297 ± 378 34 ± 268 0.006 286 ± 383 45 ± 293 0.018 
CD34+CD45dim 237 ± 333 40 ± 267 0.031 203 ± 283 74 ± 279 0.105 
CD34+VEGFR2+ 126 ± 242 44 ± 178 0.084 171 ± 298 -1 ± 85 0.002 
CD34+CD45dimVEGFR2+ 124 ± 186 5 ± 75 0.003 130 ± 175 -1 ± 75 <0.001 
Control Group       
CD34+ 332 ± 337 403 ± 641 0.468 337 ± 348 397 ± 766 0.686 
CD34+CD45dim 206 ± 278 391 ± 631 0.173 227 ± 243 380 ± 631 0.311 
CD34+VEGFR2+ 218 ± 217 85 ± 143 0.007 248 ± 213 55 ± 132 <0.001 














Figure 1. Enumeration of HCPs and EPCs by flow cytometry. 1A- Gating of the fluorescent 1 
beads from the Trucount Tubes to determine absolute cell count. 1B- Forward scatter height 2 
versus forward scatter area density plot for gating doublet exclusion. 1C- Gating of CD45+ 3 
mononuclear cells. 1D- Identification of CD45+ cells expressing CD34+ with low side scatter 4 
(CD34+ cells). 1E- Gating of low expression of CD45+ (CD34+CD45dim cells). 1F- Negative 5 
controls for the identification the gating of positive VEGFR2+ events. 1G- Identification of 6 
VEGFR2+ on CD34+ or CD34+CD45dim cells. 1H- Negative controls for the identification the 7 
gating of positive CXCR4 events. 1I- Identification of CXCR4 cell surface expression upon all 8 
HPC and EPCs phenotypes. 1J- Negative controls for the identification the gating of positive 9 
CXCR7 events. 1K- Identification of CXCR7 cell surface expression upon all HPC and EPCs 10 
phenotypes. 11 
 12 
Figure 2. Resting circulating number of CD34+, CD34+CD45dim HPCs and CD34+VEGFR2+, 13 
CD34+CD45dimVEGFR2+ EPCs (3A), and the number of these cells expressing CXCR4+ (3B) 14 
and CXCR7+ (3C) between the type 1 diabetes (red circles) and non-diabetes (blue circles) 15 
groups. # - signifies significant difference between the type 1 diabetes and non-diabetes groups. 16 



























































































































































Figure 3. The percentage of CD34+, CD34+CD45dim HPCs and CD34+VEGFR2+, 1 
CD34+CD45dimVEGFR2+ EPCs expressing CXCR4+ (A) and CXCR7+ (B) between the type 1 2 
diabetes (red circles) and non-diabetes (blue circles) groups. # - signifies significant difference 3 




Figure 4. Pre to post exercise delta change (∆ cells, cells/mL) of HPCs and EPCs (4A), HPCs 8 
and EPCs expressing CXCR4+ (4B), HPCs and EPCs expressing CXCR7+ (4C) in participants 9 
with type 1 diabetes (red circle) and non-diabetes controls (blue circle) in response to a single 10 
bout of moderate-intensity exercise. # - signifies significant difference between the type 1 11 
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